Bluebird Bio has delayed the launch of its Zynteglo gene therapy, despite securing conditional approval from Bluebird Bio , after it demanded a tightening of product specifications and manufacturing processes. Once again, manufacturing concerns are delaying access to a new, highly anticipated, and very expensive gene therapy. Bluebird has priced Zynteglo , which is for people with transfusion-dependent beta-thalassemia, at €1.575m ( $80 million ) in Europe , spread over five years . It plans to enrol its first patients by the end of this year and begin treatment in the end of this year .
Bluebird Bio has delayed the launch of its Zynteglo gene therapy, despite securing conditional approval from Bluebird Bio , after it demanded a tightening of product specifications and manufacturing processes. Bluebird has priced Zynteglo , which is for people with transfusion-dependent beta-thalassemia, at €1.575m ( $80 million ) in Europe , spread over five years . It plans to enrol its first patients by the end of this year and begin treatment in the end of this year .